MRM (MEDIROM Healthcare Technologies) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRM MEDIROM Healthcare Technologies Inc MRM
53 GF Score
Price $0.95
GF Value $4.05
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is MEDIROM Healthcare Technologies 5-Year EBITDA Growth Rate?

MEDIROM Healthcare Technologies MRM -4.10% 53 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2025. GuruFocus rates MRM with a GF Score™ of 53/100 and a GF Value™ of $4.05 (Possible Value Trap). The stock has 8 warning signs investors should review.

MEDIROM Healthcare Technologies's EBITDA per Share for the six months ended in Jun. 2025 was $-0.36.

During the past 12 months, MEDIROM Healthcare Technologies's average EBITDA Per Share Growth Rate was 65.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of MEDIROM Healthcare Technologies was 42.20% per year. The lowest was 42.20% per year. And the median was 42.20% per year.

MEDIROM Healthcare Technologies  (NAS:MRM) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

MEDIROM Healthcare Technologies 5-Year EBITDA Growth Rate Related Terms

MRM vs EJH, DROR, EVTK: 5-Year EBITDA Growth Rate Comparison

For the Personal Services subindustry, MEDIROM Healthcare Technologies's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MEDIROM Healthcare Technologies 5-Year EBITDA Growth Rate vs Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, MEDIROM Healthcare Technologies's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where MEDIROM Healthcare Technologies's 5-Year EBITDA Growth Rate falls into.


MRM
53GF Score
MEDIROM Healthcare Technologies Inc MRM
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MEDIROM Healthcare Technologies 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
MEDIROM Healthcare Technologies (MRM) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for MEDIROM Healthcare Technologies and its competitors.
Is MEDIROM Healthcare Technologies' 5-Year EBITDA Growth Rate too high?
MEDIROM Healthcare Technologies' current 5-Year EBITDA Growth Rate is 0.00%. Overall, MEDIROM Healthcare Technologies has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MEDIROM Healthcare Technologies' 5-Year EBITDA Growth Rate compare to EJH and DROR?
MEDIROM Healthcare Technologies' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Personal Services company?
A good 5-Year EBITDA Growth Rate depends on the Personal Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for MEDIROM Healthcare Technologies and its competitors. MEDIROM Healthcare Technologies's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDIROM Healthcare Technologies stock overvalued right now?
Based on GuruFocus' analysis, MEDIROM Healthcare Technologies (MRM) is currently considered Possible Value Trap. The stock's GF Value™ is $4.05, compared to a current price of $0.95 — trading 76.5% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. MEDIROM Healthcare Technologies' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For MEDIROM Healthcare Technologies (MRM), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MEDIROM Healthcare Technologies (MRM) Overvalued in 2026?

Based on GuruFocus' analysis, MEDIROM Healthcare Technologies stock appears to be undervalued. The current stock price of $0.95 is trading 76.5% below its estimated GF Value™ of $4.05. GuruFocus considers MEDIROM Healthcare Technologies to be Possible Value Trap.

Key valuation signals for MRM:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: $4.05 vs. price of $0.95 (76.5% below fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the MRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MEDIROM Healthcare Technologies Business Description

Address 2-3-1 Daiba, 16th Floor, Tradepia Odaiba, Minato-ku, Tokyo, JPN, 135-0091
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
53GF Score

Get the complete analysis for MRM

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.95
Price
$4.05
GF Value